PTC THERAPEUTICS INC (PTCT)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for PTCT
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| PTCT | Director | 80 | ["Co-founder of PTC Therapeutics, Inc.","Former Chairman of PTC Therapeutics Board from 1998 to 2004.","Chairman of the Department of Microbiology and Physiological Systems at the University of Massachusetts Chan Medical School.","Gerald L. and Zelda S. Haidak Professor of Cell Biology.","Co-founded Applied bioTechnology, Inc.","Special limited partner at Euclid Partners."] | ["Development Committee (Chair)"] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Jacobson chairs our Development Committee. Our Development Committee did not meet in 2025. Our Development Committee s responsibilities include: discussing Phase 2 and Phase 3 clinical trial protocols and regulatory strategy with our Chief Operating Officer (or equivalent position); evaluating any serious adverse event that is unexpected and deemed to be drug related (specifically death and life-threatening events) that occurs during the conduct of our clinical trials; evaluating any serious adverse event that is unexpected and deemed to be drug related (specifically death and life-threatening events) from one of our commercial products; and reporting to our Board or Audit Committee, as appropriate, regarding the progress of our clinical trials, occurrence of serious adverse events, our regulatory filings and any material compliance or legal updates related thereto.